ES2213389T3 - Antagonistas de mglur5 para el tratamiento del dolor y la ansiedad. - Google Patents

Antagonistas de mglur5 para el tratamiento del dolor y la ansiedad.

Info

Publication number
ES2213389T3
ES2213389T3 ES99948905T ES99948905T ES2213389T3 ES 2213389 T3 ES2213389 T3 ES 2213389T3 ES 99948905 T ES99948905 T ES 99948905T ES 99948905 T ES99948905 T ES 99948905T ES 2213389 T3 ES2213389 T3 ES 2213389T3
Authority
ES
Spain
Prior art keywords
mglur
pain
mglur5
antagonists
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES99948905T
Other languages
English (en)
Spanish (es)
Inventor
Hans Allgeier
Nicholas David Cosford
Peter Josef Flor
Fabrizio Gasparini
Conrad Gentsch
Stephen D. Hess
Edwin Carl Johnson
Rainer Kuhn
Mark Tricklebank
Laszlo Urban
Mark Andrew Varney
Gonul Veli Elebi
Katharine Walker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
SIBIA Neurosciences Inc
Original Assignee
Novartis AG
SIBIA Neurosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26314451&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2213389(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9821503.1A external-priority patent/GB9821503D0/en
Application filed by Novartis AG, SIBIA Neurosciences Inc filed Critical Novartis AG
Application granted granted Critical
Publication of ES2213389T3 publication Critical patent/ES2213389T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
ES99948905T 1998-10-02 1999-09-30 Antagonistas de mglur5 para el tratamiento del dolor y la ansiedad. Expired - Lifetime ES2213389T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9821503.1A GB9821503D0 (en) 1998-10-02 1998-10-02 Organic compounds
GB9821503 1998-10-02
US22081398A 1998-12-23 1998-12-23
US220813 1998-12-23

Publications (1)

Publication Number Publication Date
ES2213389T3 true ES2213389T3 (es) 2004-08-16

Family

ID=26314451

Family Applications (1)

Application Number Title Priority Date Filing Date
ES99948905T Expired - Lifetime ES2213389T3 (es) 1998-10-02 1999-09-30 Antagonistas de mglur5 para el tratamiento del dolor y la ansiedad.

Country Status (21)

Country Link
EP (1) EP1117403B1 (https=)
JP (1) JP2002526408A (https=)
KR (1) KR20010088832A (https=)
CN (1) CN1187048C (https=)
AT (1) ATE255894T1 (https=)
AU (1) AU765644B2 (https=)
BR (1) BR9914215A (https=)
CA (1) CA2345137A1 (https=)
DE (1) DE69913548T2 (https=)
DK (1) DK1117403T3 (https=)
ES (1) ES2213389T3 (https=)
HU (1) HUP0200553A3 (https=)
ID (1) ID29095A (https=)
IL (2) IL142047A0 (https=)
NO (1) NO20011440L (https=)
NZ (1) NZ510743A (https=)
PL (1) PL202906B1 (https=)
PT (1) PT1117403E (https=)
RU (1) RU2232017C2 (https=)
SK (1) SK4382001A3 (https=)
WO (1) WO2000020001A1 (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0005700D0 (en) * 2000-03-09 2000-05-03 Glaxo Group Ltd Therapy
PT1345609E (pt) 2000-12-22 2005-08-31 Hoffmann La Roche Derivados de tetra-hidro-(benzo ou tieno)-azepina-pirazina como antagonistas de mglur 1
GB0128996D0 (en) 2001-12-04 2002-01-23 Novartis Ag Organic compounds
SE0303418D0 (sv) * 2003-12-17 2003-12-17 Astrazeneca Ab New use 1
SE0303419D0 (sv) * 2003-12-17 2003-12-17 Astrazeneca Ab New use 11
FR2883180B1 (fr) * 2005-03-18 2007-05-25 Pierre Fabre Medicament Sa Utilisation de l'acetyl-leucine pour la preparation d'un medicament destine au traitement de troubles de l'equilibre
GB0525068D0 (en) 2005-12-08 2006-01-18 Novartis Ag Organic compounds
DE102005062985A1 (de) * 2005-12-28 2007-07-05 Grünenthal GmbH Substituierte bis(hetero)aromatische N-Ethylpropiolamide und ihre Verwendung zur Herstellung von Arzneimitteln
ES2610508T3 (es) 2006-11-22 2017-04-27 Clinical Research Associates, Llc Métodos para tratar el síndrome de Down, el síndrome del cromosoma X frágil y el autismo
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
US8586581B2 (en) * 2009-12-17 2013-11-19 Hoffmann-La Roche Inc Ethynyl compounds useful for treatment of CNS disorders
WO2011092290A1 (en) 2010-02-01 2011-08-04 Novartis Ag Pyrazolo[5,1b]oxazole derivatives as crf-1 receptor antagonists
AR080056A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de ciclohexil-amida como antagonistas de los receptores de crf
EP2531490B1 (en) 2010-02-02 2014-10-15 Novartis AG Cyclohexyl amide derivatives as crf receptor antagonists
US20130058915A1 (en) 2010-03-02 2013-03-07 Children's Medica Center Corporation Methods and compositions for treatment of angelman syndrome and autism spectrum disorders
WO2011150380A1 (en) 2010-05-28 2011-12-01 Xenoport, Inc. Methods of treatment of fragile x syndrome, down's syndrome, autism and related disorders
US20120016021A1 (en) 2010-07-15 2012-01-19 Xenoport, Inc. Methods of treating fragile x syndrome, down's syndrome, autism and related disorders
WO2012054724A1 (en) 2010-10-21 2012-04-26 Massachusetts Institute Of Technology Methods of treating seizure disorders
AR086554A1 (es) 2011-05-27 2014-01-08 Novartis Ag Derivados de la piperidina 3-espirociclica como agonistas de receptores de la ghrelina
EP2557183A1 (de) 2011-08-12 2013-02-13 Siemens Aktiengesellschaft Verfahren zum Betrieb einer Konti-Glühe für die Verarbeitung eines Walzguts
JP2015525202A (ja) 2012-05-03 2015-09-03 ノバルティス アーゲー グレリン受容体アゴニストとしての２，７−ジアザ−スピロ［４，５］デカ−７−イル誘導体のｌ−リンゴ酸塩およびその結晶形態
LT3303316T (lt) 2015-06-03 2020-05-11 F. Hoffmann-La Roche Ag Etinilo dariniai
CA3066711A1 (en) 2017-07-31 2019-02-07 Novartis Ag Use of mavoglurant in the reduction of cocaine use or in preventing relapse into cocaine use
EP3459939A1 (en) 2017-09-26 2019-03-27 Pragma Therapeutics Novel heterocyclic compounds as modulators of mglur7
KR102027368B1 (ko) * 2018-05-29 2019-10-01 서울대학교산학협력단 통증의 강도를 측정하는 방법

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2056983T3 (es) * 1988-03-21 1994-10-16 Boehringer Ingelheim Pharma Compuestos para inhibir la biosintesis de metabolitos de acido araquidonico derivados de lipoxigenasa.
TW544448B (en) * 1997-07-11 2003-08-01 Novartis Ag Pyridine derivatives

Also Published As

Publication number Publication date
BR9914215A (pt) 2001-07-03
CA2345137A1 (en) 2000-04-13
NZ510743A (en) 2003-10-31
NO20011440D0 (no) 2001-03-21
KR20010088832A (ko) 2001-09-28
CN1187048C (zh) 2005-02-02
NO20011440L (no) 2001-05-15
EP1117403A1 (en) 2001-07-25
EP1117403B1 (en) 2003-12-10
IL142047A0 (en) 2002-03-10
DE69913548T2 (de) 2004-09-23
AU6198499A (en) 2000-04-26
HUP0200553A2 (hu) 2002-07-29
ID29095A (id) 2001-07-26
JP2002526408A (ja) 2002-08-20
CN1321087A (zh) 2001-11-07
PL346876A1 (en) 2002-03-11
SK4382001A3 (en) 2001-08-06
AU765644B2 (en) 2003-09-25
PT1117403E (pt) 2004-04-30
RU2232017C2 (ru) 2004-07-10
IL142047A (en) 2007-09-20
DE69913548D1 (de) 2004-01-22
HUP0200553A3 (en) 2002-11-28
WO2000020001A1 (en) 2000-04-13
PL202906B1 (pl) 2009-08-31
ATE255894T1 (de) 2003-12-15
DK1117403T3 (da) 2004-04-13

Similar Documents

Publication Publication Date Title
ES2213389T3 (es) Antagonistas de mglur5 para el tratamiento del dolor y la ansiedad.
Anderson et al. [3H] Methoxymethyl-3-[(2-methyl-1, 3-thiazol-4-yl) ethynyl] pyridine binding to metabotropic glutamate receptor subtype 5 in rodent brain: in vitro and in vivo characterization
Yashpal et al. Noxious thermal and chemical stimulation induce increases in 3H-phorbol 12, 13-dibutyrate binding in spinal cord dorsal horn as well as persistent pain and hyperalgesia, which is reduced by inhibition of protein kinase C
Chen et al. Spinal endogenous acetylcholine contributes to the analgesic effect of systemic morphine in rats
ES2220727T3 (es) Antagonistas del receptor metabotropico de glutamato para tratar la tolerancia y la dependencia.
US9226918B2 (en) Methods and compositions for treating or preventing narcotic withdrawal symptoms
KR20030040201A (ko) 급성 통증, 만성 통증 및/또는 신경병성 통증 및 편두통을치료하기 위한 약학 조성물
US20010056084A1 (en) MGluR5 antagonists for the treatment of pain and anxiety
BRPI0616344A2 (pt) mÉtodo para o tratamento de dependÊncia quÍmica e comportamental
JPH09104634A (ja) 痛覚脱失を生じるためならびにニューロパシー性疼痛疾患の進行を阻害するための組成物および処方物
ES2283049T3 (es) (d)-metadona, un analgesico no opiaceo.
Kuhn et al. In vitro and in vivo characterization of MPEP, an allosteric modulator of the metabotropic glutamate receptor subtype 5
JP2012131829A (ja) そう痒状態の処置のためのｍｇｌｕｒ５アンタゴニストの使用
US20260021130A1 (en) Neurolytic agents and methods of using and identifying same
Neugebauer Glutamate receptor ligands
Bockaert et al. 5-HT4 receptors: an update
Larsen et al. Medicinal chemistry of competitive kainate receptor antagonists
Kohara et al. Antinociceptive profile of a selective metabotropic glutamate receptor 1 antagonist YM-230888 in chronic pain rodent models
JP2007519733A (ja) アンパカインにより誘導されるシナプス応答促通のコリンエステラーゼ阻害剤による増強方法
ES2370276T3 (es) Agente para la profilaxis o el tratamiento de alcoholismo o drogodependencia.
CA2238815A1 (en) Composition for treating pain
WO1997032581A1 (en) Use of 4-phenyl-3,6-dihydro-2h-pyridyl derivatives as nmda receptor subtype blockers
Mills Recent advances in neurokinin receptor antagonists
Kekesi et al. Dose-independent antinociceptive interaction of endogenous ligands at the spinal level
Sorbera et al. Aprepitant and L-758298